MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-25-2026
Pacific Biosciences of California Depreciation & Amortization 2011-2026 | PACB
Annual Depreciation & Amortization Pacific Biosciences of California
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13 M | 13.8 M | 11.5 M | 9.48 M | 7.2 M | 6.43 M | 7.26 M | 7.22 M | 8.44 M | 3.88 M | 3.68 M | 4.22 M | 5.65 M | 6.65 M | 5.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.8 M | 3.68 M | 7.61 M |
Quarterly Depreciation & Amortization Pacific Biosciences of California
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 3.24 M | - | - | - | 2.76 M | - | 6.94 M | 4.59 M | 2.27 M | - | 4.94 M | 3.2 M | 1.61 M | - | 4.83 M | 3.25 M | 1.66 M | - | 5.48 M | 3.59 M | 1.8 M | - | 5.44 M | 3.61 M | 1.8 M | - | 6.63 M | 4.84 M | 2.85 M | - | 2.82 M | 1.82 M | 848 K | - | 2.69 M | 1.85 M | 908 K | - | 3.31 M | 2.31 M | 1.22 M | - | 4.24 M | 2.9 M | 1.49 M | - | 5.04 M | 3.35 M | 1.63 M | - | 4.3 M | 2.86 M | 1.47 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.94 M | 848 K | 3.17 M |
Depreciation & Amortization of other stocks in the Diagnostics research industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
321 M | $ 115.48 | 0.82 % | $ 35.1 B |  USA |
 |
Burning Rock Biotech Limited
BNR
|
47.8 M | $ 16.2 | -0.61 % | $ 175 M |  China |
 |
Biodesix
BDSX
|
5.77 M | $ 15.07 | 2.1 % | $ 1.95 B | USA |
 |
Aspira Women's Health
AWH
|
112 K | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
1.11 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Check-Cap Ltd.
CHEK
|
161 K | - | - | $ 9.42 M |  Israel |
 |
Castle Biosciences
CSTL
|
16 M | $ 24.84 | -0.84 % | $ 690 M | USA |
 |
DarioHealth Corp.
DRIO
|
307 K | $ 8.4 | 3.7 % | $ 33.5 M | Israel |
 |
BioNano Genomics
BNGO
|
9.53 M | $ 1.2 | 0.84 % | $ 6.53 M | USA |
|
Akumin
AKU
|
98.2 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Charles River Laboratories International
CRL
|
403 M | $ 173.89 | -0.58 % | $ 8.62 B | USA |
 |
Accelerate Diagnostics
AXDX
|
1.7 M | - | -61.36 % | $ 2.46 M | USA |
 |
DexCom
DXCM
|
252 M | $ 62.22 | -0.24 % | $ 24.3 B | USA |
 |
Fulgent Genetics
FLGT
|
24.9 M | $ 16.82 | 2.31 % | $ 509 M | USA |
 |
Biomerica
BMRA
|
87 K | $ 2.17 | -0.91 % | $ 4.98 M | USA |
 |
Global Cord Blood Corporation
CO
|
43.3 M | - | - | $ 399 M | China |
 |
Celcuity
CELC
|
167 K | $ 112.63 | -0.27 % | $ 5.27 B | USA |
 |
Exact Sciences Corporation
EXAS
|
125 M | - | - | $ 19.8 B | USA |
 |
DermTech
DMTK
|
200 K | - | -11.32 % | $ 2.94 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
570 M | $ 198.02 | 0.17 % | $ 22 B | USA |
 |
Guardant Health
GH
|
39.7 M | $ 93.83 | 2.94 % | $ 11.8 B | USA |
 |
Enzo Biochem
ENZ
|
1.27 M | - | -8.98 % | $ 14.8 K | USA |
 |
Lantheus Holdings
LNTH
|
70.1 M | $ 76.1 | 0.53 % | $ 5.14 B | USA |
 |
Biocept
BIOC
|
1.66 M | - | -13.05 % | $ 7.29 M | USA |
 |
Medpace Holdings
MEDP
|
27.2 M | $ 498.34 | 1.81 % | $ 14.4 B | USA |
 |
Heska Corporation
HSKA
|
14 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
587 K | - | -20.0 % | $ 1.06 M | USA |
 |
Interpace Biosciences
IDXG
|
425 K | $ 1.96 | 5.82 % | $ 8.67 M | USA |
 |
Mettler-Toledo International
MTD
|
51.1 M | $ 1 259.94 | -1.11 % | $ 26 B |  Schweiz |
 |
ICON Public Limited Company
ICLR
|
488 M | $ 114.19 | 2.49 % | $ 9.42 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
145 M | $ 569.55 | 0.87 % | $ 45.8 B | USA |
 |
Neogen Corporation
NEOG
|
119 M | $ 9.41 | 0.21 % | $ 2.04 B | USA |
 |
Illumina
ILMN
|
354 M | $ 127.38 | 0.59 % | $ 20.3 B | USA |
 |
IQVIA Holdings
IQV
|
1.14 B | $ 173.26 | 0.5 % | $ 29.8 B | USA |
 |
QIAGEN N.V.
QGEN
|
194 M | - | - | $ 10.6 B |  Niderland |
 |
Motus GI Holdings
MOTS
|
451 K | - | -34.28 % | $ 263 K | Israel |
 |
Chembio Diagnostics
CEMI
|
2.55 M | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
681 M | $ 273.72 | 0.36 % | $ 22.8 B | USA |
 |
Myriad Genetics
MYGN
|
53.7 M | $ 4.75 | 3.49 % | $ 440 M | USA |
 |
Sotera Health Company
SHC
|
94.9 M | $ 14.96 | 0.61 % | $ 4.25 B | USA |
 |
NeoGenomics
NEO
|
36.1 M | $ 8.0 | 3.23 % | $ 1.02 B | USA |
 |
National Research Corporation
NRC
|
7.62 M | $ 17.16 | -1.04 % | $ 384 M | USA |